<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">topic on Aion Gold / Kinah Farming</style></title><secondary-title><style face="normal" font="default" size="100%">topic on Aion Gold / Kinah Farming</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">20090925</style></year></dates></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ali Raisuddin</style></author><author><style face="normal" font="default" size="100%">Bhatnagar Aseem</style></author><author><style face="normal" font="default" size="100%">Khar Roop K</style></author><author><style face="normal" font="default" size="100%">Malhotra Geena</style></author><author><style face="normal" font="default" size="100%">Sule Sunita</style></author><author><style face="normal" font="default" size="100%">Pandit Pragati</style></author><author><style face="normal" font="default" size="100%">Ahmad Farhan J</style></author><author><style face="normal" font="default" size="100%">Jain Gaurav K</style></author><author><style face="normal" font="default" size="100%">Iqbal Zeenat</style></author><author><style face="normal" font="default" size="100%">Talegaonkar Sushama</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote </style></title><secondary-title><style face="normal" font="default" size="100%">Nanomedicine: Nanotechnology, Biology and Medicine, </style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2009</style></date></pub-dates></dates><section><style face="normal" font="default" size="100%">55</style></section><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">55-63</style></pages><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">P. V. Ingle</style></author><author><style face="normal" font="default" size="100%">V. G. Kuchake</style></author><author><style face="normal" font="default" size="100%">A. R. Tekade</style></author><author><style face="normal" font="default" size="100%">P. H. Patil</style></author><author><style face="normal" font="default" size="100%">S. J. Surana</style></author><author><style face="normal" font="default" size="100%">P. P. Bhattad</style></author><author><style face="normal" font="default" size="100%">Senthamarai. R</style></author><author><style face="normal" font="default" size="100%">Ismail. A. M</style></author><author><style face="normal" font="default" size="100%">G. S. Talele</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Potentiality of a newer oral antihyperglycemic combination therapy over conventional one</style></title><secondary-title><style face="normal" font="default" size="100%">The IXth World Conference on Clinical Pharmacology and Therapeutics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diabetes Mellitus</style></keyword><keyword><style  face="normal" font="default" size="100%">Glycosylated hemoglobin</style></keyword><keyword><style  face="normal" font="default" size="100%">HbA1c</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008 July 27</style></date></pub-dates></dates><pub-location><style face="normal" font="default" size="100%">Quebec, Canada.</style></pub-location><abstract><style face="normal" font="default" size="100%">Potentiality of a Newer Oral Antihyperglycemic Combination Therapy over
Conventional One
P. V. Ingle, V. G. Kuchake, A. R. Tekade, P. H. Patil, S. J. Surana,
P. P. Bhattad, Senthamarai. R., Ismail. A. M., G. S. Talele.
1R. C. Patel College of Pharmacy, Shirpur, India, 2Periyar College of Pharmaceutical
Sciences for Girl’s, Tiruchirappalli, India, 3Jalgaon Zillha Medicine Dealers Society’s
College of Pharmacy, Mamurabad, India
The Aim of this study is to perceive the “Potentiality of a newer oral antihyperglycemic
combination therapy over conventional ones” &amp; “aid and assist” the people with type 2
diabetes mellitus. Main objective is to compare efficacy of newer oral antihyperglycemic
combination therapy over conventional ones in the therapy of type 2 diabetes mellitus by
finding out the effect of these two varied combinations on glycemic control by monitoring
fasting plasma glucose (FPG), glycosylated haemoglobin (HbA1c), the Lipid Profile and
the body mass index (BMI). Major Findings - In the glibenclamide plus metformin
combination therapy (n = 23) group FPG &amp; HbA1c decreased during the therapy
significantly up to − 49.06 mg/dL &amp; − 0.90 % respectively during the 4 months of study
period. In the glimepiride plus metformin combination therapy group (n = 15) FPG &amp;
HbA1c decreased during the therapy significantly up to − 55.44 mg/dL &amp; − 1.28 %
respectively during the 4 months of study period. It was found that combination therapy
with metformin plus glimepiride is more effective than glibenclamide plus metformin in
improving glycemic control in type 2 diabetes mellitus and is a beneficial adjunct to
diet/exercise in management of type 2 diabetes mellitus. At the end of the study period in
glimepiride combination therapy more patients were observed to have ≤ 8% of HbA1c
(60.00 %) as compared to glibenclamide combination therapy (39.13 %). Reduction in
BMI and in total and LDL cholesterol level were not too significant.</style></abstract><notes><style face="normal" font="default" size="100%">Got Travel Grant $1,000.00 CAD from “Canadian Society for Clinical Pharmacology AND National Research Council of Canada”, for attending the “THE IXth WORLD CONFERENCE ON CLINICAL PHARMACOLOGY AND THERAPEUTICS” going to be held at QUEBEC, CANADA. 2008 July 27- August 01.</style></notes></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>47</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sandeep Kale</style></author><author><style face="normal" font="default" size="100%">Yogesh Mishra</style></author><author><style face="normal" font="default" size="100%">Arvind Lali</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reverse Phase Chromatographic Purification of Biotherapeutic Peptide Intermediate </style></title><secondary-title><style face="normal" font="default" size="100%">Indian Pharmaceutical Congress, Ahmedabad, india</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">11/12/2009</style></date></pub-dates></dates></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>47</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sandeep Kale</style></author><author><style face="normal" font="default" size="100%">Gaurangi Deore</style></author><author><style face="normal" font="default" size="100%">Arvind Lali</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Selective extraction and purification of Scopoletin from Artemisia annua</style></title><secondary-title><style face="normal" font="default" size="100%">Indian Pharmaceutical Congress, Ahmedabad, India</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">11/12/2009</style></date></pub-dates></dates></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>47</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sandeep Kale</style></author><author><style face="normal" font="default" size="100%">Monika Raina</style></author><author><style face="normal" font="default" size="100%">Arvind Lali</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mono/Polyclonal Antibodies: Efficient and Cost Effective Purification Using Novel Pseudobioaffinity Media</style></title><secondary-title><style face="normal" font="default" size="100%">Indian Pharmaceutical Congress, Ahmedabad, India</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">11/12/2009</style></date></pub-dates></dates></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>47</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sandeep Kale</style></author><author><style face="normal" font="default" size="100%">Monika Raina</style></author><author><style face="normal" font="default" size="100%">Gaurangi Deore</style></author><author><style face="normal" font="default" size="100%">Arvind Lali</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">‘AbSep’ Based Pseudobioaffinity Chromatographic Purification of Protein Biotherapeutics: MAb/PAb</style></title><secondary-title><style face="normal" font="default" size="100%">International Conference on Biotechnology and Food Science, Bangalore, India</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">09/02/2010</style></date></pub-dates></dates></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>32</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">J.A.PATEL</style></author></authors><tertiary-authors><author><style face="normal" font="default" size="100%">R.Y.CHAUDHARI</style></author></tertiary-authors><translated-authors><author><style face="normal" font="default" size="100%">J.D.FEGDE</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">SYTHESIS AND PHARMACOLOGICAL SCREENING OF BENZOTHIAZOLE DERIVATIVES</style></title><secondary-title><style face="normal" font="default" size="100%">PHARMA CHEM</style></secondary-title><short-title><style face="normal" font="default" size="100%">2323</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">12W3E</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">08/2009</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">NORTH MAHARASHTRA UNIVERSITY</style></publisher><orig-pub><style face="normal" font="default" size="100%">344</style></orig-pub><pub-location><style face="normal" font="default" size="100%">JALGAON</style></pub-location><volume><style face="normal" font="default" size="100%">M.PHARA</style></volume><pages><style face="normal" font="default" size="100%">1</style></pages><isbn><style face="normal" font="default" size="100%">1234</style></isbn><work-type><style face="normal" font="default" size="100%">SYNTHESIS</style></work-type><accession-num><style face="normal" font="default" size="100%">1234</style></accession-num><call-num><style face="normal" font="default" size="100%">1234</style></call-num></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M.S. Wani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Formulation And In-Vitro Evaluation of Praval Bhasma Tablet</style></title><secondary-title><style face="normal" font="default" size="100%">Asian Journal of Pharmaceutics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year><pub-dates><date><style  face="normal" font="default" size="100%">04/2007</style></date></pub-dates></dates><section><style face="normal" font="default" size="100%">96</style></section><volume><style face="normal" font="default" size="100%">1</style></volume><pages><style face="normal" font="default" size="100%">4</style></pages><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Future of Cancer Therapy-COX-2 Inhibitors: A Review</style></title><secondary-title><style face="normal" font="default" size="100%">Research Journal of Pharmacy and Technology </style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">Submitted</style></year></dates><volume><style face="normal" font="default" size="100%">2</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue></record></records></xml>